Recent Advances in Anticancer Strategies, 2nd Edition

Abstract submission deadline

31 January 2026

Manuscript submission deadline

31 March 2026

Viewed by

4864

Topic Information

Dear Colleagues,

The topic "Recent Advances in Anticancer Strategies, 2nd Edition" aims to provide an overview of the latest developments in the field of cancer treatment. Cancer remains one of the leading causes of death worldwide, and researchers have been working to develop more effective and targeted treatments to improve outcomes for patients. The existing cancer therapies suffer from severe side-effects and drug resistance, leading to an increase in cancer incidence and mortality worldwide. Hence, there is a pressing need to develop and discover novel therapeutic strategies that can offer more effective and less-toxic treatment options for cancer patients. Novel anticancer approaches are being developed which can selectively identify and eliminate cancerous cells while minimizing harm to healthy tissues, unlike traditional therapies.

For this topic, we welcome original articles and comprehensive reviews that showcase the latest advances in novel anticancer strategies with reduced toxicity and improved therapeutic indices. These articles can suggest potential prospects for optimizing cancer therapies with significant clinical value in the near future. We encourage submissions that focus on the development and validation of various anticancer approaches, including ligand-/receptor-based targeting, controlled drug delivery, gene therapy, gene delivery, immunotherapy, targeted anticancer prodrugs and conjugates (such as photoactivatable caged prodrugs, ADEPT, ADAPT, and ADCs), magnetic- and ultrasound-mediated drug targeting, and cancer stem cell therapy, as well as strategies that explore the targeting of signaling cascades and the tumor microenvironment.

Overall, this topic aims at providing recent advances in anticancer strategies, highlighting the potential impact of these new approaches on cancer treatment and patient outcomes. We eagerly anticipate your valuable contribution to this exciting topic.

Dr. Hassan Bousbaa
Dr. Zhiwei Hu
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
Cancers cancers	4.5	8.0	2009	17.4 Days	CHF 2900	Submit
International Journal of Molecular Sciences ijms	4.9	8.1	2000	16.8 Days	CHF 2900	Submit
Pharmaceuticals pharmaceuticals	4.3	6.1	2004	13.9 Days	CHF 2900	Submit
Pharmaceutics pharmaceutics	4.9	7.9	2009	15.5 Days	CHF 2900	Submit
Scientia Pharmaceutica scipharm	2.3	4.6	1930	26.1 Days	CHF 1000	Submit
Current Oncology curroncol	2.8	3.3	1994	19.8 Days	CHF 2200	Submit
Molecules molecules	4.2	7.4	1996	15.1 Days	CHF 2700	Submit

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Related Topic

Published Papers (4 papers)

Order results

Content type Publication Date

Result details

Normal Extended Compact

Journals

All Cancers IJMS Pharmaceuticals Pharmaceutics Sci. Pharm. Current Oncology Molecules

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

Error

Oops... you haven't selected anything for export.

Ok

clear

20 pages, 663 KiB  

Open AccessSystematic Review

Electrochemotherapy in the Management of Keratinocyte Carcinomas: A Systematic Review

by Yue Ting Nichole Tan and Choon Chiat Oh

Cancers 2025, 17(11), 1766; https://doi.org/10.3390/cancers17111766 (registering DOI) - 24 May 2025

Abstract

Background: Keratinocyte carcinomas, including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), presents a growing concern. Electrochemotherapy (ECT), an emerging treatment modality, combines chemotherapy and electroporation to enhance drug delivery into cells. However, reviews evaluating ECT in keratinocyte carcinomas are lacking. Objectives: [...] Read more.

Background: Keratinocyte carcinomas, including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), presents a growing concern. Electrochemotherapy (ECT), an emerging treatment modality, combines chemotherapy and electroporation to enhance drug delivery into cells. However, reviews evaluating ECT in keratinocyte carcinomas are lacking. Objectives: This study reviews the efficacy and toxicity of ECT in the treatment and palliation of keratinocyte carcinomas. Methods: A systematic search was conducted across PubMed, Cochrane, Embase, and Scopus databases. Patient, tumor, and treatment characteristics, tumor response, long-term disease outcomes, and toxicity data were extracted. Quality of studies was assessed using validated tools. Primary endpoints included tumor response; secondary endpoints included long-term disease outcomes and toxicity. Results: Twenty-one studies were included. Complete response (CR) rates ranged from 50 to 100% and from 10 to 100% for BCC and SCC, respectively. OS rates ranged from 95 (14 months) to 100 (1 year) % and from 64 (1 year) to 85.1 (8.6 months) % for BCC and SCC, respectively. One-year local disease-free survival (LDFS) rates were 89% and 87% for BCC and SCC, respectively. For BCC, local progression-free survival (LPFS) rates were 96% (1 year), 90% (2 year), and 70% (5 year). For SCC, 1-year LPFS rates were 80% on a per-patient basis and 49% on a per-lesion basis. Conclusions: ECT is effective and tolerable in the treatment and palliation of keratinocyte carcinomas. Future studies should focus on improving reporting quality, optimizing treatment protocols, and investigating long-term outcomes. Full article

(This article belongs to the Topic Recent Advances in Anticancer Strategies, 2nd Edition)

►▼ Show Figures

Figure 1

attachment

Supplementary material:
Supplementary File 1 (ZIP, 840 KiB)

32 pages, 6286 KiB  

Open AccessArticle

Synthesis and In Vitro Evaluation of the Anticancer Effect of Novel Phosphonium Vindoline Derivatives

by Mónika Halmai, Viktória Donkó-Tóth, Péter Keglevich, Károly Kánai, Márton Weber, Miklós Dékány, Ejlal A. Abdallah, Noémi Bózsity, István Zupkó, Andrea Nehr-Majoros, Éva Szőke, Zsuzsanna Helyes and László Hazai

Int. J. Mol. Sci. 2025, 26(8), 3775; https://doi.org/10.3390/ijms26083775 - 16 Apr 2025

Viewed by 415

Abstract

The Vinca alkaloid vindoline was coupled at position 17 with several trisubstituted phosphine derivatives and their in vitro anticancer activities on 60 human tumor cell lines (NCI60) were investigated. This phosphonium-type ionic side chain is beneficial because it allows therapeutic molecules to pass [...] Read more.

The Vinca alkaloid vindoline was coupled at position 17 with several trisubstituted phosphine derivatives and their in vitro anticancer activities on 60 human tumor cell lines (NCI60) were investigated. This phosphonium-type ionic side chain is beneficial because it allows therapeutic molecules to pass through the cell membrane. Thus, the candidates coupled to it can exert their activities in the mitochondria. The coupling of vindoline with the trisubstituted phosphines was achieved through flexible or rigid linkers. Instead of the ionic phosphonium structural part, a neutral moiety, namely the triphenylmethyl group, was also added to the side chain, being sterically similar but without a charge and phosphorus atom. In addition, the triphenylphosphine element was also built at position 10 of vindoline. Most of the derivatives showed low micromolar growth inhibition (GI₅₀) values against most cell lines. Among them, conjugate 9e was outstanding: it exhibited nanomolar anticancer activity on the RPMI-8226 leukemia cell line (GI₅₀ = 20.0 nM). Compound 9g elicited cell cycle disturbance and apoptosis on A2780 ovary cancer cells and inhibited their migration at subantiproliferative concentrations. The selectivity of the conjugates was determined by their effects on non-tumor Chinese hamster ovary (CHO) cells in the CellTiter-Glo Luminescent Cell Viability Assay. Compound 9e showed an estimated half-maximal inhibitory concentration (IC₅₀) value of 1.36 µM, suggesting good selectivity on cancer cells. These results open new perspectives of novel phosphonium-based vindoline derivatives as anticancer compounds. Full article

(This article belongs to the Topic Recent Advances in Anticancer Strategies, 2nd Edition)

►▼ Show Figures

Figure 1

22 pages, 1121 KiB  

Open AccessReview

Advancing Cancer Treatment and Diagnosis: A Review on Photodynamic Therapy Using OLED Technology

by Rajesh Kumar Tiwari, Rajesh Mishra, Sanjay Kumar Sharma, Nakshathra Prabhu, Mangey Ram Nagar and Saulius Grigalevicius

Molecules 2025, 30(6), 1305; https://doi.org/10.3390/molecules30061305 - 14 Mar 2025

Cited by 1 | Viewed by 1303

Abstract

Photodynamic therapy (PDT) is an innovative and non-invasive approach to treating apparent tumours with minimal toxicity. PDT has a long-standing application in antitumor treatment utilizing various photosensitizers (PSs) for different tumours. Historically, light has served as a therapeutic tool in many diseases. PDT [...] Read more.

Photodynamic therapy (PDT) is an innovative and non-invasive approach to treating apparent tumours with minimal toxicity. PDT has a long-standing application in antitumor treatment utilizing various photosensitizers (PSs) for different tumours. Historically, light has served as a therapeutic tool in many diseases. PDT involves a dual treatment process in which light energy and PSs are combined to ablate tumour cells following light activation. In general, PDT exhibits reduced side effects and toxicity compared to chemotherapy and radiotherapy, as it spares the extracellular matrix, facilitating excellent tissue healing and minimizing scarring. In addition, PSs can serve in diagnostic roles in tumour identification, termed photodynamic diagnosis (PDD). Advancements in flexible light sources that produce uniform illumination could significantly enhance the consistency of light delivery. This review outlines the clinical applications of OLEDs in PDT for cancer, addressing both diagnostic and therapeutic methods. Furthermore, we will explore various tumour cases using PDT with OLEDs. In particular, antimicrobial PDT targets antibiotic-resistant strains in diabetic foot ulcers, while metronomic PDT promotes cancer cell apoptosis through prolonged, low-intensity light exposure. Our emphasis is on PDT employing organic light-emitting diodes (OLEDs). Furthermore, the combination of PDT with NIR-OLEDs is examined for its potential to enhance tumour-targeting effectiveness, possibly exceeding the results of standalone treatments. Full article

(This article belongs to the Topic Recent Advances in Anticancer Strategies, 2nd Edition)

►▼ Show Figures

Figure 1

28 pages, 2851 KiB  

Open AccessReview

Targeting c-MYC G-Quadruplexes for Cancer Treatment with Small Molecules

by Prasanth Thumpati, Sachchida Nand Rai, Chandrabhan Prajapati, Kakarla Ramakrishna and Santosh Kumar Singh

Sci. Pharm. 2025, 93(1), 6; https://doi.org/10.3390/scipharm93010006 - 22 Jan 2025

Cited by 7 | Viewed by 1739

Abstract

Novel therapies are required due to the rising cancer burden. Conventional chemotherapeutics tend to be particularly toxic, but there is a promising alternative for oncogenes, such as c-MYC. Often overexpressed in many cancer types, the potential c-MYC oncogene seems essential to the development [...] Read more.

Novel therapies are required due to the rising cancer burden. Conventional chemotherapeutics tend to be particularly toxic, but there is a promising alternative for oncogenes, such as c-MYC. Often overexpressed in many cancer types, the potential c-MYC oncogene seems essential to the development of cancer. Targeting c-MYC protein directly was limited, but these DNA structures composed of guanine-rich sequences suppress c-MYC transcription. This review discusses recent advances in developing small compounds that selectively bind to and stabilize c-MYC G-quadruplexes (G4). These molecules have also shown promise for the inhibition of c-MYC signaling and inhibition of tumor growth, suggesting that G-quadruplex targeting could be a promising therapeutic for cancer. Full article

(This article belongs to the Topic Recent Advances in Anticancer Strategies, 2nd Edition)

►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

 

Error

Oops... you haven't selected anything for export.

Ok

clear

Displaying articles 1-4